Premium
Polyspecific malaria antibodies present at the time of infection inhibit the development of immunity to malaria but antibodies specific for the malaria merozoite surface protein, MSP1, facilitate immunity
Author(s) -
Zhang Wenbao,
Liu Xue Qin,
Xu Huji,
Good Michael F.
Publication year - 2002
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1046/j.1365-3024.2002.00456.x
Subject(s) - malaria , immunity , plasmodium yoelii , biology , immunology , antibody , immune system , humoral immunity , virology , merozoite surface protein , malaria vaccine , plasmodium falciparum , parasitemia
Summary Serum taken from mice immune to malaria as a result of infection and drug cure, or from mice immunized with a recombinant form of the merozoite surface protein, MSP1, can provide passive protection of recipient mice against the lethal parasite, Plasmodium yoelii YM . However, recipients of MSP1‐immune serum go on to develop long‐term immunity, whereas recipients of serum from mice naturally immune to malaria rapidly lose their resistance to infection. We demonstrate that ‘infection/cure’ serum suppresses the development of both antibody and cell‐mediated parasite‐specific responses in recipients, whereas these develop in recipients of MSP1‐specific antibodies. These data have profound implications for our understanding of the development of malaria immunity in babies who passively acquire antibodies from their mothers.